TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00833638
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally once daily
Study: NCT01356017
Drug: Telmisartan 80mg, S-amlodipine 5mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study: NCT01356017
Drug: Telmisartan 80mg
Normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study: NCT00364429
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Drug
Study: NCT00364429
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study Drug
Study: NCT00307827
Drug: Visilizumab
Normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visilizumab administered intravenously once per day for two days
Study: NCT04047862
Drug: Ociperlimab
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous (IV) injection
Study: NCT04047862
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV injection
Study: NCT04047862
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered in accordance with local guidelines, prescribing information/summary of product
Study: NCT04047862
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT00793468
Drug: Nicotine Replacement Transdermal Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
Study: NCT01357967
Drug: SSRI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
Study: NCT01357967
Drug: Seroquel XR adjunctive
Normalized name: quetiapine Extended Release Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime
Study: NCT02348073
Drug: Vayarin®, supplementation of n-3 PUFA
DrugBank: Vayarin (DB09328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product.
Study: NCT03969719
Drug: PF-06835919
Normalized name: PF-06835919
DrugBank: PF-06835919 (DB19163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg once daily
Study: NCT03969719
Drug: PF-06835919
Normalized name: PF-06835919
DrugBank: PF-06835919 (DB19163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg once daily
Study: NCT01166633
Drug: pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pitavastatin 2mg per daily
Study: NCT01166633
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10mg per daily
Study: NCT00983073
Drug: Tapentadol
Normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period.
Study: NCT01029223
Drug: ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01029223
Drug: metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01373528
Drug: Budesonide irrigation
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
Study: NCT00229333
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00229125
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00229125
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00058123
Drug: poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02130193
Drug: Danirixin
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
Study: NCT03166761
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection into the sacroiliac joint
Study: NCT03166761
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone injection into the sacroiliac joint
Study: NCT01833741
Drug: Bimatoprost 0.01%
Normalized name: BIMATOPROST 0.01% OPH SOLN
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
Study: NCT01511432
Drug: telaprevir formulation A
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 1125-mg dose administered orally
Study: NCT01511432
Drug: telaprevir Formulation B
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 1125-mg dose administered orally
Study: NCT01511432
Drug: telaprevir Formulation C
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 1125-mg dose administered orally
Study: NCT01511432
Drug: telaprevir Formulation D
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 1125-mg dose administered orally
Study: NCT00295061
Drug: Alpha-1 MP
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
Study: NCT00295061
Drug: alpha-1 proteinase inhibitor (human)
Normalized name: Alpha-1 proteinase inhibitor (human)
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin
Study: NCT00626561
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg IV twice weekly on days 1 and 15.
Study: NCT00626561
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
Study: NCT00101283
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
Study: NCT00101283
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
Study: NCT00101283
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
Study: NCT00327626
Drug: ISIS 113715
Normalized name: ISIS 113715
DrugBank: ISIS 113715 (DB05506)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00277667
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
Study: NCT01839929
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01839929
Drug: Advagraf
Normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00624299
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botox injection (100 ius) per muscle
Study: NCT02393794
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Histone deacetylase inhibitor
Study: NCT02393794
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Platinum compound
Study: NCT02393794
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody, checkpoint inhibitor
Study: NCT00636610
Drug: Vismodegib 150 mg
Normalized name: vismodegib 150 MG
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
Study: NCT00636610
Drug: Placebo to vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
Study: NCT00636610
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
Study: NCT02495272
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 10IU Administered intramuscularly.
Study: NCT01308242
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer 800 mg by mouth three times daily with meals for 3 months
Study: NCT00002528
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
Study: NCT01427608
Drug: Sertraline + Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
Study: NCT01427608
Drug: Sertraline + Placebo
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
Study: NCT02390284
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
Study: NCT02390284
Drug: Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.
Study: NCT02390284
Drug: Travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.
Study: NCT02390284
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lower intraocular pressure by decreasing production of fluid
Study: NCT02390284
Drug: Dorzolamide
Normalized name: Dorzolamide
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study: NCT02390284
Drug: Brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study: NCT02390284
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study: NCT00843661
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg ezetimibe/day
Study: NCT00843661
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg fenofibrate/day
Study: NCT00390208
Drug: ranibizumab, dexamethasone and verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
Study: NCT00390208
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 0.5 mg intravitreal Ranibizumab injection
Study: NCT01964079
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Study: NCT02390284
Drug: Methazolamide
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study: NCT01964079
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Study: NCT03576664
Drug: Carvedilol 25mg
Normalized name: CARVEDILOL 25MG TAB
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over, randomized, placebo-controlled study.
Study: NCT01457937
Drug: Pegylated Interferon, Ribavirin, Boceprevir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)
Study: NCT02585778
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study: NCT00261950
Drug: Sensipar (Cinacalcet HCl)
Normalized name: Sensipar
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
Study: NCT01313585
Drug: Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01141205
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2 ml saline intramuscularly
Study: NCT02477618
Drug: SAGE-547
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02198027
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
Study: NCT03961165
Drug: Butylscopolamine Bromide 20 MG/ML
Normalized name: butylscopolamine bromide 20 MG/ML
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
Study: NCT03961165
Drug: Sodium Chloride 9mg/mL
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
Study: NCT00428350
Drug: Quetiapine Fumarate (Seroquel)
Normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003718
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03053050
Drug: SEL
Normalized name: Selen
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00104572
Drug: Androgel (Testosterone Gel)
Normalized name: testosterone Topical Gel [Androgel]
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablet for 12 months
Study: NCT00104572
Drug: Anastrozole (Aromatase Inhibitor)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03010683
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
Study: NCT03010683
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
Study: NCT04469777
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Study: NCT00537511
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00537511
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00537511
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02333591
Drug: GlucagonLikePeptide-1 (7-36)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
Study: NCT02333591
Drug: GlucagonLikePeptide-1 (9-36)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
Study: NCT02333591
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused intravenously for 2,5 hours.
Study: NCT01204697
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 intravenously every 3 weeks for 4 cycles